A first-in-human, randomized, double-blind, single-ascending-dose study of recombinant human thymosin β4 | RemedyX Labs Research Library

A research summary of A first-in-human, randomized, double-blind, single-ascending-dose study of recombinant human thymosin β4, covering TB-500 in the context of phase 1 human trial research. Cited source and RUO context from RemedyX Labs.